OARS funding Cancer

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

This FOA seeks to stimulate basic inquiry into the mechanisms that influence people within their larger social contexts to manage one or multiple conditions over the lifecourse. Long-term goals are to increase knowledge of the individual and group processes that inform thought and behaviors that reinforce health and optimal wellbeing to enhance overall human health, reduce illness and disability, and lengthen life.

This FOA seeks to stimulate basic inquiry into the mechanisms that influence people within their larger social contexts to manage one or multiple conditions over the lifecourse. Long-term goals are to increase knowledge of the individual and group processes that inform thought and behaviors that reinforce health and optimal wellbeing to enhance overall human health, reduce illness and disability, and lengthen life.

I-Corps@Ohio is a statewide program to assist faculty and graduate students from Ohio universities and colleges to validate the market potential of their technologies and assist with launching startup companies. I-Corps@Ohio is modeled after the National Science Foundation's (NSF) successful I-Corps program, which has proven to increase innovation, entrepreneurship, and industry collaboration. I-Corps@Ohio is an initiative of the Ohio Department of Higher Education.

Together with University Advancement, the Office for the Advancement of Research & Scholarship (OARS) is rolling out an new crowdfunding platform called HawksNest. Through HawksNest, alumni, family, and friends of the university can directly support the research, scholarship, and service projects of Miami University students, faculty, and staff. This is how HawksNest works: * Any Miami University student, faculty, or staff member may complete an online application to have a project considered for funding. * An internal review team assesses applications and posts approved projects on HawksNest for a maximum of 45 days. * Potential donors visit the site to learn about and pledge funds to approved projects. * Once a funding goal has been met, the project can begin! * Project managers use the site to keep donors up-to-date with information on the project's progress.

The Physics Division, through the Physics of Living Systems program, accepts and reviews investigator-initiated proposals on the interdisciplinary topic of theoretical physics in cancer biology. Proposals may involve joint efforts between investigators from theoretical physics and researchers from the biomedical community, although the focus of the project must be on the role that physics plays in the effort.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes.

In an effort to confront the crisis arising from a growing dearth of physician-scientists, Damon Runyon wishes to encourage more physicians to pursue research careers. To do so, the Foundation is establishing a pilot program designed to recruit outstanding U.S. Specialty Board-eligible physicians into cancer research careers by providing them with the opportunity for a protected research training experience under the mentorship of a highly qualified and gifted mentor after they have completed all of their clinical training.

The Stand Up To Cancer (SU2C),  Innovative Research Grant is open to early-career scientists whose novel, high-risk, high-reward cancer research proposals have significant potential for translational application and hold great promise for advancing SU2C's overarching goal of improving and saving the lives of patients. Letters of Intent may focus on any discipline within basic, translational, or clinical cancer research. Projects that are currently supported by NIH R01 grants or the equivalent will not be accepted.

This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. 

The NIH Directors Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.

This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for imaging, detecting, diagnosing, preventing, and/or treating cancers in humans living in LMICs.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes.

The ASGE Endoscopic Research Awards are offered to physicians for projects in basic, translational and clinical endoscopic research. ASGE is particularly interested in endoscopic research pertaining to Barrett's esophagus, capsule endoscopy, colorectal cancer, endoscopic issues specific to under-represented minorities (defined as women and individuals of diverse ethnic/cultural backgrounds), controlled trials in endoscopic ultrasound, endoscopic retrograde cholangiopancreatography (ERCP), endoscopic optical recognition techniques, measuring quality in endoscopy, NOTES™, and novel endoscopic treatments for obesity. 

This Funding Opportunity Announcement (FOA) is a part of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics and accelerates research in these areas by disseminating research resources for the scientific community. The program will support broad efforts focused on several cancer types to explore further the complexities of cancer proteomes and their connections to abnormalities in cancer genomes.

This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for imaging, detecting, diagnosing, preventing, and/or treating cancers in humans living in LMICs.

This Funding Opportunity Announcement encourages research projects focused on the process of effective communication of research findings about breast cancer and the environment. A central objective of this new initiative is to ensure that risk messaging is designed for dissemination and effectively implemented, and leads to individual behavior change or policy change.The ultimate goal is to provide the development, dissemination, and implementation communication-based prevention efforts to reduce the risk for breast cancer from environmental factors.

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of cancer research. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to pursue research within the context of an existing cancer research program, but not serve as independent investigators.

his reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics and accelerates research in these areas by disseminating research resources for the scientific community. The program will support broad efforts focused on several cancer types to explore further the complexities of cancer proteomes and their connections to abnormalities in cancer genomes. The potential of proteomic and proteo-genomic approaches will also be explored in translational research focused on clinically-relevant problems.

This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy.